- Home
- QNRX vs HSCS Comparison
QNRX vs HSCS Comparison
Compare QNRX & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- HSCS
- Stock Information
- Founded
- QNRX 2018
- HSCS 2007
- Country
- QNRX United States
- HSCS United States
- Employees
- QNRX N/A
- HSCS N/A
- Industry
- QNRX Medical/Dental Instruments
- HSCS Medical Specialities
- Sector
- QNRX Health Care
- HSCS Health Care
- Exchange
- QNRX Nasdaq
- HSCS Nasdaq
- Market Cap
- QNRX 3.3M
- HSCS 3.7M
- IPO Year
- QNRX N/A
- HSCS 2022
- Fundamental
- Price
- QNRX $9.60
- HSCS $3.87
- Analyst Decision
- QNRX
- HSCS Strong Buy
- Analyst Count
- QNRX 0
- HSCS 2
- Target Price
- QNRX N/A
- HSCS $13.00
- AVG Volume (30 Days)
- QNRX 12.9K
- HSCS 68.9K
- Earning Date
- QNRX 08-07-2025
- HSCS 07-28-2025
- Dividend Yield
- QNRX N/A
- HSCS N/A
- EPS Growth
- QNRX N/A
- HSCS N/A
- EPS
- QNRX N/A
- HSCS N/A
- Revenue
- QNRX N/A
- HSCS N/A
- Revenue This Year
- QNRX N/A
- HSCS N/A
- Revenue Next Year
- QNRX N/A
- HSCS N/A
- P/E Ratio
- QNRX N/A
- HSCS N/A
- Revenue Growth
- QNRX N/A
- HSCS 261.17
- 52 Week Low
- QNRX $5.01
- HSCS $2.36
- 52 Week High
- QNRX $54.95
- HSCS $5.77
- Technical
- Relative Strength Index (RSI)
- QNRX 64.78
- HSCS 52.06
- Support Level
- QNRX $8.04
- HSCS $3.66
- Resistance Level
- QNRX $8.58
- HSCS $4.03
- Average True Range (ATR)
- QNRX 0.46
- HSCS 0.30
- MACD
- QNRX 0.04
- HSCS 0.01
- Stochastic Oscillator
- QNRX 98.57
- HSCS 41.11
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.